marginally significantP = 0.078
Although there was no statistically significant difference at the conventional level ( P < 0.05), the polypharmacy group exhibited a marginally significant association with an increased risk of having BMS (OR = 2.066, 95% CI: 0.922–4.630, P = 0.078, Table 3 ).